Welcome to This Is MS!

     Modules
· Home
· Content
· Downloads
· Encyclopedia
· FAQ
· Feedback
· Forums
· Journal
· Private Messages
· Recommend Us
· Search
· Site_Map
· Stories Archive
· Submit News
· Surveys
· Top 10
· Topics
· Web Links
· Your Account

     Google
Google
Web
This is MS
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS.

     Languages
Select Interface Language:


     Who's Online
There are currently, 51 guest(s) and 7 member(s) that are online.

You are Anonymous user. You can register for free by clicking here

     Next Step

From the creators of This is MS comes Experience Project

EP is a community where members connect through shared life experiences-- like MS--and so much more. You are not defined by any one thing, so be your true self and find others just like you at Experience Project.

Get started by sharing your Multiple Sclerosis story.


     Donations

To remain unbiased, This is MS does not accept corporate sponsorships.

Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you!
 News: Elan's Investor Conference Call Notes Regarding Tysabri

Tysabri (Antegren or Natalizumab)Elan had their conference call shortly following Biogen's. They did not say much more than Biogen with respect to Tysabri. Our notes:

  • The market uptake of Tysabri has thus far exceeded all expectations after just nine weeks on the market.

  • Approximately 3000 patients are already on Tysabri, with multiples of that number waiting to start.

  • Users are coming from all three categories: switchers from other treatments, dropouts who are not on therapy, and newly diagnosed.

  • Launch of Tysabri in the European Union for both Chron's Disease and MS in late 2005 or early 2006.

  • Tysabri AFFIRM (monotherapy) data will be available in April at the AAN meeting.

  • Elan is in discussions with BiogenIdec over whether they make an endpoint success announcement in the meantime.

  • Phase II data for Tysabri Rheumatoid Arthritis indication by mid year.

We hope you've found this information useful. It is very revealing to get multiple viewpoints on these drugs from both the medical community as well as the investors.

If you're interested in listening to the archived call, please click "read more."

Advertisement

Link to Archived Conference Call

Please click here




 
     Login
Nickname

Password

Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name.

     Related Links
· More about Tysabri (Antegren or Natalizumab)
· News by Administrator
Most read story about Tysabri (Antegren or Natalizumab):
Revealing Medical History of 3rd Tysabri Patient with PML


     Article Rating
Average Score: 0
Votes: 0

Please take a second and vote for this article:

Excellent
Very Good
Good
Regular
Bad


     Options

 Printer Friendly Printer Friendly






Personal Stories about millions of life experience--including multiple sclerosis support, lupus support, depression support . Built by the This is MS team.

Anonymous Confessions | Dream Dictionary
Site Map

This site does not offer medical advice. All treatment decisions should always be made with the full consent of your physician.


Visit our sister site dedicated to Inflammatory Bowel Disease: This is IBD


All logos and trademarks in this site are property of their respective owners. The comments are property of their posters, quoted articles are © referenced source, all the rest © 2002 by thisisMS.com.
PHP-Nuke Copyright © 2005 by Francisco Burzi. This is free software, and you may redistribute it under the GPL. PHP-Nuke comes with absolutely no warranty, for details, see the license.
Page Generation: 0.08 Seconds